Huperzine A and memory: grade C

Limited evidence. Direction: Benefit.

C LimitedShort-term onlySingle research group

Educational guidance, not medical advice

Why this grade

Rubric condition met: Single small placebo-controlled matched-pair trial, in adolescents rather than adults (C); not B under the rubric (one trial, under 100 participants, funding not stated)

The one placebo-controlled trial of repeated dosing in people without a diagnosis that we found is a 1999 double-blind, matched-pair trial in 34 pairs of junior middle school students who complained of poor memory; after 4 weeks of two 50 microgram capsules twice daily, memory quotient was higher than with placebo. It is small, from one research group, in adolescents rather than adults, and its funding is not stated. A single-dose study in healthy young adults found 200 micrograms maintained declarative recall but did not improve other measures, and a 12-week trial after moderate-severe brain injury found no difference from placebo, so the proposal is C.

How we grade evidence

Studies this grade rests on

each study this grade rests on, by publication year and design. Solid: effect versus the comparator; half-filled: mixed; hollow: no effect; dashed: result not recorded yet. Larger marks had more participants.

Show the numbers

Study	Year	Design	Participants	Result
Sun 1999	1999	double-blind, placebo-controlled, matched-pair trial (4 weeks; groups matched on memory quotient, sex and class; randomization not stated in the abstract)	68	result not recorded
Morasch 2015	2015	RCT	not recorded	result not recorded
Zafonte 2020	2020	RCT	not recorded	result not recorded

Huperzine A for the treatment of cognitive, mood, and functional deficits after moderate and severe TBI (HUP-TBI): results of a Phase II randomized controlled pilot study: implications for understanding the placebo effect.

Zafonte RD, Fregni F, Bergin MJG. Huperzine A for the treatment of cognitive, mood, and functional deficits after moderate and severe TBI (HUP-TBI): results of a Phase II randomized controlled pilot study: implications for understanding the placebo effect Brain Inj, 2020. PMID 31638455

Result not recorded

Design: Phase II randomized, double-blind, placebo-controlled pilot trial (12 weeks)
Population: People with moderate-severe traumatic brain injury (clinical population)
Funding: NIH extramural and US Government support (PubMed publication types); funder not named in the abstract; full text not read

Physiological and neurobehavioral effects of cholinesterase inhibition in healthy adults.

Morasch KC, Aaron CL, Moon JE. Physiological and neurobehavioral effects of cholinesterase inhibition in healthy adults Physiol Behav, 2015. PMID 25455867

Result not recorded

Design: Randomized, placebo-controlled single-dose study (7 arms, n=12 per drug/dose)
Population: Healthy young adults
Funding: US Government support, non-PHS, and non-US Government support (PubMed publication types); funder not named in the abstract; full text not read

Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students.

Sun QQ, Xu SS, Pan JL. Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students Zhongguo Yao Li Xue Bao, 1999. PMID 10678121

Result not recorded

Design: Double-blind, placebo-controlled, matched-pair trial (4 weeks; groups matched on memory quotient, sex and class; randomization not stated in the abstract)
Sample: n = 68
Population: Junior middle school students (adolescents) complaining of memory inadequacy, China
Funding: not stated in the PubMed or Crossref record; full text not read

Search and history

Search (November 11, 2026): huperzine[ti] AND (memory[tiab]) AND (adolescent*[tiab] OR student*[tiab] OR young[tiab])

November 12, 2026 Graded C (proposed): Proposed in the monograph draft
November 13, 2026 C to C (approved): Editor sign-off November 13, 2026: grade matches the editor-approved final page